

# REFERENCES

## SECTION 1: QUALITY PERINATAL CARE IS YOUR RIGHT

1. Cleveland, L. M., Bonugli, R. J., & McGlothen, K. S. (2016). The Mothering Experiences of Women With Substance Use Disorders. *ANS. Advances in nursing science*, 39(2), 119–129. <https://doi.org/10.1097/ANS.000000000000118>
2. Torchalla, I., Linden, I. A., Strehlau, V., Neilson, E. K., & Krausz, M. (2015). "Like a lot happened with my whole childhood": violence, trauma, and addiction in pregnant and postpartum women from Vancouver's Downtown Eastside. *Harm reduction journal*, 11, 34. <https://doi.org/10.1186/1477-7517-11-34>
3. Cunningham, J. A., Sobell, L. C., & Chow, V. M. (1993). What's in a label? The effects of substance types and labels on treatment considerations and stigma. *Journal of studies on alcohol*, 54(6), 693–699. <https://doi.org/10.15288/jsa.1993.54.693>
4. Pauly B. (2008). Harm reduction through a social justice lens. *The International journal on drug policy*, 19(1), 4–10. <https://doi.org/10.1016/j.drugpo.2007.11.005>
5. British Columbia Provincial Mental Health and Substance Use Planning Council. (2013). *Trauma-Informed Practice Guide*. [https://bccewh.bc.ca/wp-content/uploads/2012/05/2013\\_TIP-Guide.pdf](https://bccewh.bc.ca/wp-content/uploads/2012/05/2013_TIP-Guide.pdf)
6. Poole, N., & Greaves, L. (2012). *Becoming trauma informed*. Centre for Addiction and Mental Health.
7. Nathoo, T., Poole, N., Bryans, M., Dechief, L., Hardeman, S., Marcellus, L., ... Taylor, M. (2013). Voices from the community: Developing effective community programs to support pregnant and early parenting women who use alcohol and other substances. *First Peoples Child Family Review*, 8(1), 93–106. <https://doi.org/10.7202/1071409AR>
8. Beck, C. T., Driscoll, J., & Watson, S. (2013). *Traumatic childbirth*. Routledge.
9. Vedam, S., Stoll, K., Taiwo, T. K., Rubashkin, N., Cheyney, M., Strauss, N., McLemore, M., Cadena, M., Nethery, E., Rushton, E., Schummers, L., Declercq, E., & GVtM-US Steering Council (2019). The Giving Voice to Mothers study: inequity and mistreatment during pregnancy and childbirth in the United States. *Reproductive health*, 16(1), 77. <https://doi.org/10.1186/s12978-019-0729-2>
10. Abrahams, R. R., Kelly, S. A., Payne, S., Thiessen, P. N., Mackintosh, J., & Janssen, P. A. (2007). Rooming-in compared with standard care for newborns of mothers using methadone or heroin. *Canadian family physician Medecin de famille canadien*, 53(10), 1722–1730.
11. Moore, E. R., Anderson, G. C., Bergman, N., & Dowswell, T. (2012). Early skin-to-skin contact for mothers and their healthy newborn infants. *The Cochrane database of systematic reviews*, 5(5), CD003519. <https://doi.org/10.1002/14651858.CD003519.pub3>
12. Pepler, D. J., Motz, M., Leslie, M., Jenkins, J., Espinet, S. D., Reynolds, W. (2014). *The Mother-Child Study: Evaluating Treatments for Substance-using Women*. Mothercraft Press.
13. Kendall-Tackett K. A. (2007). Violence against women and the perinatal period: the impact of lifetime violence and abuse on pregnancy, postpartum, and breastfeeding. *Trauma, violence & abuse*, 8(3), 344–353. <https://doi.org/10.1177/1524838007304406>
14. Seng, J. S., Sperlich, M., Low, L. K., Ronis, D. L., Muzik, M., & Liberzon, I. (2013). Childhood abuse history, posttraumatic stress disorder, postpartum mental health, and bonding: a prospective cohort study. *Journal of midwifery & women's health*, 58(1), 57–68. <https://doi.org/10.1111/j.1542-2011.2012.00237.x>

## SECTION 2: HARM REDUCTION

1. Centers for Disease Control and Prevention. (2021, December 14). Alcohol use during pregnancy. Centers for Disease Control and Prevention. Retrieved October 2, 2022, from <https://www.cdc.gov/ncbddd/fasd/alcohol-use.html>
2. Riley, E. P., Infante, M. A., & Warren, K. R. (2011). Fetal alcohol spectrum disorders: an overview. *Neuropsychology review*, 21(2), 73–80. <https://doi.org/10.1007/s11065-011-9166-x>
3. Centers for Disease Control and Prevention. (2021, May 14). Key findings: The effects of alcohol use during pregnancy and later developmental outcomes: An analysis of previous studies. Centers for Disease Control and Prevention. Retrieved October 2, 2022, from <https://www.cdc.gov/ncbddd/fasd/features/key-finding-acer.html>
4. Committee opinion no. 496: At-risk drinking and alcohol dependence: obstetric and gynecologic implications. (2011). *Obstetrics and gynecology*, 118(2 Pt 1), 383–388. <https://doi.org/10.1097/AOG.0b013e31822c9906>
5. Liston J. (1998). Breastfeeding and the use of recreational drugs--alcohol, caffeine, nicotine and marijuana. *Breastfeeding review : professional publication of the Nursing Mothers' Association of Australia*, 6(2), 27–30.
6. Ogawa, Y., Takeshima, N., & Furukawa, T. A. (2018). Maternal exposure to benzodiazepine and risk of preterm birth and low birth weight: A case-control study using a claims database in Japan. *Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists*, 10(3), e12309. <https://doi.org/10.1111/appy.12309>
7. Okun, M. L., Ebert, R., & Saini, B. (2015). A review of sleep-promoting medications used in pregnancy. *American journal of obstetrics and gynecology*, 212(4), 428–441. <https://doi.org/10.1016/j.ajog.2014.10.1106>
8. Zwink, N., & Jenetzky, E. (2018). Maternal drug use and the risk of anorectal malformations: systematic review and meta-analysis. *Orphanet journal of rare diseases*, 13(1), 75. <https://doi.org/10.1186/s13023-018-0789-3>
9. Reichner C. A. (2015). Insomnia and sleep deficiency in pregnancy. *Obstetric medicine*, 8(4), 168–171. <https://doi.org/10.1177/1753495X15600572>
10. Iqbal, M. M., Sobhan, T., & Ryals, T. (2002). Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. *Psychiatric services (Washington, D.C.)*, 53(1), 39–49. <https://doi.org/10.1176/appi.ps.53.1.39>
11. Soyka M. (2017). Treatment of Benzodiazepine Dependence. *The New England journal of medicine*, 376(24), 2399–2400. <https://doi.org/10.1056/NEJMc1705239>
12. Fried P. A. (1995). Prenatal exposure to marijuana and tobacco during infancy, early and middle childhood: effects and an attempt at synthesis. *Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement*, 17, 233–260. [https://doi.org/10.1007/978-3-642-79451-3\\_21](https://doi.org/10.1007/978-3-642-79451-3_21)
13. Day, N. L., Richardson, G. A., Geva, D., & Robles, N. (1994). Alcohol, marijuana, and tobacco: effects of prenatal exposure on offspring growth and morphology at age six. *Alcoholism, clinical and experimental research*, 18(4), 786–794. <https://doi.org/10.1111/j.1530-0277.1994.tb00041.x>
14. Braillon, A., & Bewley, S. (2018). Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. *Obstetrics and gynecology*, 131(1), 164. <https://doi.org/10.1097/AOG.0000000000002429>
15. Torres, C. A., Medina-Kirchner, C., O'Malley, K. Y., & Hart, C. L. (2020). Totality of the Evidence Suggests Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments: A Systematic and Critical Review. *Frontiers in psychology*, 11, 816. <https://doi.org/10.3389/fpsyg.2020.00816>

## SECTION 2: HARM REDUCTION

16. Corsi, D. J., Walsh, L., Weiss, D., Hsu, H., El-Chaar, D., Hawken, S., Fell, D. B., & Walker, M. (2019). Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. *JAMA*, 322(2), 145–152. <https://doi.org/10.1001/jama.2019.8734>
17. Bertrand, K. A., Hanan, N. J., Honerkamp-Smith, G., Best, B. M., & Chambers, C. D. (2018). Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk. *Pediatrics*, 142(3), e20181076. <https://doi.org/10.1542/peds.2018-1076>
18. Perez-Reyes, M., & Wall, M. E. (1982). Presence of delta9-tetrahydrocannabinol in human milk. *The New England journal of medicine*, 307(13), 819–820. <https://doi.org/10.1056/NEJM198209233071311>
19. Hill, M., & Reed, K. (2013). Pregnancy, breast-feeding, and marijuana: a review article. *Obstetrical & gynecological survey*, 68(10), 710–718. <https://doi.org/10.1097/01.ogx.0000435371.51584.d1>
20. Section on Breastfeeding (2012). Breastfeeding and the use of human milk. *Pediatrics*, 129(3), e827–e841. <https://doi.org/10.1542/peds.2011-3552>
21. Reece-Stremtan, S., & Marinelli, K. A. (2015). ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. *Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine*, 10(3), 135–141. <https://doi.org/10.1089/bfm.2015.9992>
22. Metz, T. D., & Stickrath, E. H. (2015). Marijuana use in pregnancy and lactation: a review of the evidence. *American journal of obstetrics and gynecology*, 213(6), 761–778. <https://doi.org/10.1016/j.ajog.2015.05.025>
23. Baker, T., Datta, P., Rewers-Felkins, K., Thompson, H., Kallem, R. R., & Hale, T. W. (2018). Transfer of Inhaled Cannabis Into Human Breast Milk. *Obstetrics and gynecology*, 131(5), 783–788. <https://doi.org/10.1097/AOG.0000000000002575>
24. Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. (2017). *Obstetrics and gynecology*, 130(2), e81–e94. <https://doi.org/10.1097/AOG.0000000000002235>
25. Dickmann, L. J., & Isoherranen, N. (2013). Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy. *Drug metabolism and disposition: the biological fate of chemicals*, 41(2), 270–274. <https://doi.org/10.1124/dmd.112.047118>
26. Hepburn, M. (2004). *Current Obstetrics and Gynaecology*, 14(6), 419–425. <https://doi.org/https://doi.org/10.1016/j.curobgyn.2004.07.006>
27. Kashiwagi, M., Arlettaz, R., Lauper, U., Zimmermann, R., & Hebisch, G. (2005). Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies. *Acta obstetrica et gynecologica Scandinavica*, 84(2), 140–144. <https://doi.org/10.1111/j.0001-6349.2005.00497.x>
28. Pace, C. A., Kaminetzky, L. B., Winter, M., Cheng, D. M., Saia, K., Samet, J. H., & Walley, A. Y. (2014). Postpartum changes in methadone maintenance dose. *Journal of substance abuse treatment*, 47(3), 229–232. <https://doi.org/10.1016/j.jsat.2014.04.004>
29. Shiu, J. R., & Ensom, M. H. (2012). Dosing and monitoring of methadone in pregnancy: literature review. *The Canadian journal of hospital pharmacy*, 65(5), 380–386. <https://doi.org/10.4212/cjhp.v65i5.1176v>
30. Wolff, K., Boys, A., Rostami-Hodjegan, A., Hay, A., & Raistrick, D. (2005). Changes to methadone clearance during pregnancy. *European journal of clinical pharmacology*, 61(10), 763–768. <https://doi.org/10.1007/s00228-005-0035-5>

## SECTION 2: HARM REDUCTION

31. Wong, S., Ordean, A., Kahan, M., & Society of Obstetricians and Gynecologists of Canada (2011). SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 114(2), 190–202. <https://doi.org/10.1016/j.ijgo.2011.06.001>
32. Behnke, M., Smith, V. C., Committee on Substance Abuse, & Committee on Fetus and Newborn (2013). Prenatal substance abuse: short- and long-term effects on the exposed fetus. *Pediatrics*, 131(3), e1009–e1024. <https://doi.org/10.1542/peds.2012-3931>
33. Lind, J. N., Interrante, J. D., Ailes, E. C., Gilboa, S. M., Khan, S., Frey, M. T., Dawson, A. L., Honein, M. A., Dowling, N. F., Razzaghi, H., Creanga, A. A., & Broussard, C. S. (2017). Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review. *Pediatrics*, 139(6), e20164131. <https://doi.org/10.1542/peds.2016-4131>
34. Bada, H. S., Das, A., Bauer, C. R., Shankaran, S., Lester, B. M., Gard, C. C., Wright, L. L., Lagasse, L., & Higgins, R. (2005). Low birth weight and preterm births: etiologic fraction attributable to prenatal drug exposure. *Journal of perinatology : official journal of the California Perinatal Association*, 25(10), 631–637. <https://doi.org/10.1038/sj.jp.7211378>
35. Cleary, B. J., Eogan, M., O'Connell, M. P., Fahey, T., Gallagher, P. J., Clarke, T., White, M. J., McDermott, C., O'Sullivan, A., Carmody, D., Gleeson, J., & Murphy, D. J. (2012). Methadone and perinatal outcomes: a prospective cohort study. *Addiction (Abingdon, England)*, 107(8), 1482–1492. <https://doi.org/10.1111/j.1360-0443.2012.03844.x>
36. Cleary, B. J., Donnelly, J. M., Strawbridge, J. D., Gallagher, P. J., Fahey, T., White, M. J., & Murphy, D. J. (2011). Methadone and perinatal outcomes: a retrospective cohort study. *American journal of obstetrics and gynecology*, 204(2), 139.e1–139.e1399. <https://doi.org/10.1016/j.ajog.2010.10.004>
37. Hulse, G. K., Milne, E., English, D. R., & Holman, C. D. (1997). Assessing the relationship between maternal cocaine use and abruptio placentae. *Addiction (Abingdon, England)*, 92(11), 1547–1551.
38. Wurst, K. E., Zedler, B. K., Joyce, A. R., Sasinowski, M., & Murrelle, E. L. (2016). A Swedish Population-based Study of Adverse Birth Outcomes among Pregnant Women Treated with Buprenorphine or Methadone: Preliminary Findings. *Substance abuse : research and treatment*, 10, 89–97. <https://doi.org/10.4137/SART.S38887>
39. Center for Substance Abuse Treatment. (2005). Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Substance Abuse and Mental Health Services Administration (US).
40. National Library of Medicine. (n.d.). Drugs and lactation database (lactmed) - NCBI bookshelf. LactMed. Retrieved October 2, 2022, from <https://www.ncbi.nlm.nih.gov/books/NBK501922/>
41. Montgomery, A., Hale, T. W., & Academy Of Breastfeeding Medicine (2012). ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. *Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine*, 7(6), 547–553. <https://doi.org/10.1089/bfm.2012.9977>
42. Ilett, K. F., Hackett, L. P., Gower, S., Doherty, D. A., Hamilton, D., & Bartu, A. E. (2012). Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. *Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine*, 7, 269–274. <https://doi.org/10.1089/bfm.2011.0096>
43. Lindemalm, S., Nydert, P., Svensson, J. O., Stahle, L., & Sarman, I. (2009). Transfer of buprenorphine into breast milk and calculation of infant drug dose. *Journal of human lactation : official journal of International Lactation Consultant Association*, 25(2), 199–205. <https://doi.org/10.1177/0890334408328295>

## SECTION 2: HARM REDUCTION

44. Kelty, E., & Hulse, G. (2017). A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls. *Drugs*, 77(11), 1199–1210. <https://doi.org/10.1007/s40265-017-0762-9>
45. Wachman, E. M., Saia, K., Miller, M., Valle, E., Shrestha, H., Carter, G., Werler, M., & Jones, H. (2019). Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. *Clinical therapeutics*, 41(9), 1681–1689. <https://doi.org/10.1016/j.clinthera.2019.07.003>
46. Ward, E. N., Quaye, A. N., & Wilens, T. E. (2018). Opioid Use Disorders: Perioperative Management of a Special Population. *Anesthesia and analgesia*, 127(2), 539–547. <https://doi.org/10.1213/ANE.0000000000003477>
47. Jones, H. E., Chisolm, M. S., Jansson, L. M., & Terplan, M. (2013). Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. *Addiction (Abingdon, England)*, 108(2), 233–247. <https://doi.org/10.1111/j.1360-0443.2012.03811.x>
48. Chan, C. F., Page-Sharp, M., Kristensen, J. H., O'Neil, G., & Ilett, K. F. (2004). Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milk. *Journal of human lactation: official journal of International Lactation Consultant Association*, 20(3), 322–326. <https://doi.org/10.1177/0890334404266881>
49. Hulse, G. K., O'Neill, G., Pereira, C., & Brewer, C. (2001). Obstetric and neonatal outcomes associated with maternal naltrexone exposure. *The Australian & New Zealand journal of obstetrics & gynaecology*, 41(4), 424–428. <https://doi.org/10.1111/j.1479-828x.2001.tb01322.x>
50. Hulse, G., & O'Neil, G. (2002). Using naltrexone implants in the management of the pregnant heroin user. *The Australian & New Zealand journal of obstetrics & gynaecology*, 42(5), 569–573. [https://doi.org/10.1111/j.0004-8666.2002.548\\_14.x](https://doi.org/10.1111/j.0004-8666.2002.548_14.x)
51. Hulse, G. K., O'Neil, G., & Arnold-Reed, D. E. (2004). Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*, 85(2), 170–171. <https://doi.org/10.1016/j.ijgo.2003.10.001>
52. Jones, H. E., Chisolm, M. S., Jansson, L. M., & Terplan, M. (2013). Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research. *Addiction (Abingdon, England)*, 108(2), 233–247. <https://doi.org/10.1111/j.1360-0443.2012.03811.x>
53. Kelty, E., & Hulse, G. (2017). A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates. *Drugs*, 77(11), 1211–1219. <https://doi.org/10.1007/s40265-017-0763-855>
54. Coluzzi, F., Bifulco, F., Cuomo, A., Dauri, M., Leonardi, C., Melotti, R. M., Natoli, S., Romualdi, P., Savoia, G., & Corcione, A. (2017). The challenge of perioperative pain management in opioid-tolerant patients. *Therapeutics and clinical risk management*, 13, 1163–1173. <https://doi.org/10.2147/TCRM.S141332>
55. Harrison, T. K., Kornfeld, H., Aggarwal, A. K., & Lembke, A. (2018). Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy. *Anesthesiology clinics*, 36(3), 345–359. <https://doi.org/10.1016/j.anclin.2018.04.002>
56. Jansson, L. M. (n.d.). UpToDate. Retrieved October 2, 2022, from <https://www.uptodate.com/contents/neonatal-abstinence-syndrome>



## SECTION 2: HARM REDUCTION

57. Bell, J., Towers, C. V., Hennessy, M. D., Heitzman, C., Smith, B., & Chattin, K. (2016). Detoxification from opiate drugs during pregnancy. *American journal of obstetrics and gynecology*, 215(3), 374.e1–374.e3746. <https://doi.org/10.1016/j.ajog.2016.03.015>
58. Chhabra, N., Mir, M., Hua, M. J., Berg, S., Nowinski-Konchak, J., Aks, S., Arunkumar, P., & Hinami, K. (2022). Notes From the Field: Xylazine-Related Deaths - Cook County, Illinois, 2017-2021. *MMWR. Morbidity and mortality weekly report*, 71(13), 503–504. <https://doi.org/10.15585/mmwr.mm7113a3>
59. Zibbell, J. E., Clarke, S. D., Kral, A. H., Richardson, N. J., Cauchon, D., & Aldridge, A. (2022). Association between law enforcement seizures of illicit drugs and drug overdose deaths involving cocaine and methamphetamine, Ohio, 2014-2019. *Drug and alcohol dependence*, 232, 109341. <https://doi.org/10.1016/j.drugalcdep.2022.109341>
60. Moss, M. J., Warrick, B. J., Nelson, L. S., McKay, C. A., Dubé, P. A., Gosselin, S., Palmer, R. B., & Stolbach, A. I. (2017). ACMT and AACT Position Statement: Preventing Occupational Fentanyl and Fentanyl Analog Exposure to Emergency Responders. *Journal of medical toxicology : official journal of the American College of Medical Toxicology*, 13(4), 347–351. <https://doi.org/10.1007/s13181-017-0628-2>
61. Attaway, P. R., Smiley-McDonald, H. M., Davidson, P. J., & Kral, A. H. (2021). Perceived occupational risk of fentanyl exposure among law enforcement. *The International journal on drug policy*, 95, 103303. <https://doi.org/10.1016/j.drugpo.2021.103303>
62. Del Pozo, B., Sights, E., Kang, S., Goulka, J., Ray, B., & Beletsky, L. A. (2021). Can touch this: training to correct police officer beliefs about overdose from incidental contact with fentanyl. *Health & justice*, 9(1), 34. <https://doi.org/10.1186/s40352-021-00163-5>
63. Ruiz-Colón, K., Chavez-Arias, C., Díaz-Alcalá, J. E., & Martínez, M. A. (2014). Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature. *Forensic science international*, 240, 1–8. <https://doi.org/10.1016/j.forsciint.2014.03.015>
64. Torruella R. A. (2011). Xylazine (veterinary sedative) use in Puerto Rico. *Substance abuse treatment, prevention, and policy*, 6, 7. <https://doi.org/10.1186/1747-597X-6-7>
65. Rodríguez, N., Vargas Vidot, J., Panelli, J., Colón, H., Ritchie, B., & Yamamura, Y. (2008). GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. *Drug and alcohol dependence*, 96(3), 290–293. <https://doi.org/10.1016/j.drugalcdep.2008.03.005>
66. Friedman, J., Montero, F., Bourgois, P., Wahbi, R., Dye, D., Goodman-Meza, D., & Shover, C. (2022). Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. *Drug and alcohol dependence*, 233, 109380. <https://doi.org/10.1016/j.drugalcdep.2022.109380>
67. Reyes, J. C., Negrón, J. L., Colón, H. M., Padilla, A. M., Millán, M. Y., Matos, T. D., & Robles, R. R. (2012). The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. *Journal of urban health : bulletin of the New York Academy of Medicine*, 89(3), 519–526. <https://doi.org/10.1007/s11524-011-9662-6>
68. Philadelphia Department of Public Health. (2022). Risks of xylazine use and withdrawal in people who use drugs in Philadelphia. *PDPH-HAN\_Alert\_1\_Xylazine\_03.16.2022.pdf* (<http://production-philly-private-assets.s3.amazonaws.com>)
69. McNinch, JR; Maguire, M; Wallace, L. A CASE OF SKIN NECROSIS CAUSED BY INTRAVENOUS XYLAZINE ABUSE. Abstract published at SHM Converge 2021. Abstract 559 *Journal of Hospital Medicine*. <https://shabstracts.org/abstract/a-case-of-skin-necrosis-caused-by-intravenous-xylazine-abuse/>. June 15th 2022.

## SECTION 2: HARM REDUCTION

70. The New York Times Editorial Board. (2018, December 28). Slandering the unborn. The New York Times. Retrieved October 2, 2022, from <https://www.nytimes.com/interactive/2018/12/28/opinion/crack-babies-racism.html>
71. Committee Opinion No. 479: Methamphetamine abuse in women of reproductive age. (2011). *Obstetrics and gynecology*, 117(3), 751–755. <https://doi.org/10.1097/AOG.0b013e318214784e>
72. Andrade C. (2018). Risk of Major Congenital Malformations Associated With the Use of Methylphenidate or Amphetamines in Pregnancy. *The Journal of clinical psychiatry*, 79(1), 18f12108. <https://doi.org/10.4088/JCP.18f12108>
73. Forray, A., & Foster, D. (2015). Substance Use in the Perinatal Period. *Current psychiatry reports*, 17(11), 91. <https://doi.org/10.1007/s11920-015-0626-5>
74. Gorman, M. C., Orme, K. S., Nguyen, N. T., Kent, E. J., 3rd, & Caughey, A. B. (2014). Outcomes in pregnancies complicated by methamphetamine use. *American journal of obstetrics and gynecology*, 211(4), 429.e1–429.e4297. <https://doi.org/10.1016/j.ajog.2014.06.005>
75. Huybrechts, K. F., Bröms, G., Christensen, L. B., Einarsdóttir, K., Engeland, A., Furu, K., Gissler, M., Hernandez-Diaz, S., Karlsson, P., Karlstad, Ø., Kieler, H., Lahesmaa-Korpinen, A. M., Mogun, H., Nørgaard, M., Reutfors, J., Sørensen, H. T., Zoega, H., & Bateman, B. T. (2018). Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. *JAMA psychiatry*, 75(2), 167–175. <https://doi.org/10.1001/jamapsychiatry.2017.3644>
76. Shah, R., Diaz, S. D., Arria, A., LaGasse, L. L., Derauf, C., Newman, E., Smith, L. M., Huestis, M. A., Haning, W., Strauss, A., Della Grotta, S., Dansereau, L. M., Roberts, M. B., Neal, C., & Lester, B. M. (2012). Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. *American journal of perinatology*, 29(5), 391–400. <https://doi.org/10.1055/s-0032-1304818>
77. Wright, T. E., Schuetter, R., Tellei, J., & Sauvage, L. (2015). Methamphetamines and pregnancy outcomes. *Journal of addiction medicine*, 9(2), 111–117. <https://doi.org/10.1097/ADM.000000000000101>
78. Good, M. M., Solt, I., Acuna, J. G., Rotmensch, S., & Kim, M. J. (2010). Methamphetamine use during pregnancy: maternal and neonatal implications. *Obstetrics and gynecology*, 116(2 Pt 1), 330–334. <https://doi.org/10.1097/AOG.0b013e3181e67094>
79. Nguyen, D., Smith, L. M., Lagasse, L. L., Derauf, C., Grant, P., Shah, R., Arria, A., Huestis, M. A., Haning, W., Strauss, A., Della Grotta, S., Liu, J., & Lester, B. M. (2010). Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. *The Journal of pediatrics*, 157(2), 337–339. <https://doi.org/10.1016/j.jpeds.2010.04.024>
80. Richardson, G. A., & Day, N. L. (1994). Detrimental effects of prenatal cocaine exposure: illusion or reality?. *Journal of the American Academy of Child and Adolescent Psychiatry*, 33(1), 28–34. <https://doi.org/10.1097/00004583-199401000-00005>
81. Richardson, G. A., Hamel, S. C., Goldschmidt, L., & Day, N. L. (1999). Growth of infants prenatally exposed to cocaine/crack: comparison of a prenatal care and a no prenatal care sample. *Pediatrics*, 104(2), e18. <https://doi.org/10.1542/peds.104.2.e18>
82. Shankaran, S., Lester, B. M., Das, A., Bauer, C. R., Bada, H. S., Lagasse, L., & Higgins, R. (2007). Impact of maternal substance use during pregnancy on childhood outcome. *Seminars in fetal & neonatal medicine*, 12(2), 143–150. <https://doi.org/10.1016/j.siny.2007.01.002>

## SECTION 2: HARM REDUCTION

83. La Leche League International. (2021, June 1). Breastfeeding and caffeine. La Leche League International. Retrieved October 2, 2022, from <https://www.llli.org/breastfeeding-info/caffeine/>
84. Chasnoff, I. J., Burns, K. A., & Burns, W. J. (1987). Cocaine use in pregnancy: perinatal morbidity and mortality. *Neurotoxicology and teratology*, 9(4), 291–293. [https://doi.org/10.1016/0892-0362\(87\)90017-1](https://doi.org/10.1016/0892-0362(87)90017-1)
85. Mastrogiannis, D. S., Decavalas, G. O., Verma, U., & Tejani, N. (1990). Perinatal outcome after recent cocaine usage. *Obstetrics and gynecology*, 76(1), 8–11.
86. Slutsker L. (1992). Risks associated with cocaine use during pregnancy. *Obstetrics and gynecology*, 79(5 ( Pt 1)), 778–789.
87. ACOG Practice Bulletin No. 102: management of stillbirth. (2009). *Obstetrics and gynecology*, 113(3), 748–761. <https://doi.org/10.1097/AOG.0b013e31819e9ee2>
88. Little, B. B., Snell, L. M., Trimmer, K. J., Ramin, S. M., Ghali, F., Blakely, C. A., & Garret, A. (1999). Peripartum cocaine use and adverse pregnancy outcome. *American journal of human biology : the official journal of the Human Biology Council*, 11(5), 598–602. [https://doi.org/10.1002/\(SICI\)1520-6300\(199909/10\)11:5<598::AID-AJHB3>3.0.CO;2-L](https://doi.org/10.1002/(SICI)1520-6300(199909/10)11:5<598::AID-AJHB3>3.0.CO;2-L)
89. Aghamohammadi, A., & Zafari, M. (2016). Crack abuse during pregnancy: maternal, fetal and neonatal complication. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*, 29(5), 795–797. <https://doi.org/10.3109/14767058.2015.1018821>
90. Hulse, G. K., Milne, E., English, D. R., & Holman, C. D. (1997). Assessing the relationship between maternal cocaine use and abruptio placentae. *Addiction (Abingdon, England)*, 92(11), 1547–1551.
91. Eze, N., Smith, L. M., LaGasse, L. L., Derauf, C., Newman, E., Arria, A., Huestis, M. A., Della Grotta, S. A., Dansereau, L. M., Neal, C., & Lester, B. M. (2016). School-Aged Outcomes following Prenatal Methamphetamine Exposure: 7.5-Year Follow-Up from the Infant Development, Environment, and Lifestyle Study. *The Journal of pediatrics*, 170, 34–8.e1. <https://doi.org/10.1016/j.jpeds.2015.11.070>
92. Bartu, A., Dusci, L. J., & Ilett, K. F. (2009). Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. *British journal of clinical pharmacology*, 67(4), 455–459. <https://doi.org/10.1111/j.1365-2125.2009.03366.x>
93. Cressman, A. M., Koren, G., Pupco, A., Kim, E., Ito, S., & Bozzo, P. (2012). Maternal cocaine use during breastfeeding. *Canadian family physician Medecin de famille canadien*, 58(11), 1218–1219.
94. Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017). The Safety of Ingested Caffeine: A Comprehensive Review. *Frontiers in psychiatry*, 8, 80. <https://doi.org/10.3389/fpsy.2017.00080>
95. Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use disorders: an update. *Journal of substance abuse treatment*, 23(2), 145–150. [https://doi.org/10.1016/s0740-5472\(02\)00256-8](https://doi.org/10.1016/s0740-5472(02)00256-8)
96. Farsalinos, K. E., & Le Houezec, J. (2015). Regulation in the face of uncertainty: the evidence on electronic nicotine delivery systems (e-cigarettes). *Risk management and healthcare policy*, 8, 157–167. <https://doi.org/10.2147/RMHP.S62116>



## SECTION 2: HARM REDUCTION

97. Foulds, J., Ramstrom, L., Burke, M., & Fagerström, K. (2003). Effect of smokeless tobacco (snus) on smoking and public health in Sweden. *Tobacco control*, 12(4), 349–359. <https://doi.org/10.1136/tc.12.4.349>
98. Royal College of Physicians. (2007, October). Harm reduction in nicotine addiction: Helping people who can't quit. RCP London. Retrieved October 2, 2022, from <https://shop.rcplondon.ac.uk/products/harm-reduction-in-nicotine-addiction-helping-people-who-cant-quit?variant=6509405637>
99. Narahashi, T., Fenster, C. P., Quick, M. W., Lester, R. A., Marszalec, W., Aistrup, G. L., Sattelle, D. B., Martin, B. R., & Levin, E. D. (2000). Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior. *Toxicological sciences : an official journal of the Society of Toxicology*, 57(2), 193–202. <https://doi.org/10.1093/toxsci/57.2.193>
100. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Review of the Health Effects of Electronic Nicotine Delivery Systems, Eaton, D. L., Kwan, L. Y., & Stratton, K. (Eds.). (2018). *Public Health Consequences of E-Cigarettes*. National Academies Press (US).
101. Law, K. L., Stroud, L. R., LaGasse, L. L., Niaura, R., Liu, J., & Lester, B. M. (2003). Smoking during pregnancy and newborn neurobehavior. *Pediatrics*, 111(6 Pt 1), 1318–1323. <https://doi.org/10.1542/peds.111.6.1318>
102. Stroud, L. R., Paster, R. L., Papandonatos, G. D., Niaura, R., Salisbury, A. L., Battle, C., Lagasse, L. L., & Lester, B. (2009). Maternal smoking during pregnancy and newborn neurobehavior: effects at 10 to 27 days. *The Journal of pediatrics*, 154(1), 10–16. <https://doi.org/10.1016/j.jpeds.2008.07.048>
103. Committee Opinion No. 721: Smoking Cessation During Pregnancy. (2017). *Obstetrics and gynecology*, 130(4), 1. <https://doi.org/10.1097/AOG.0000000000002353>
104. Einarson, A., & Riordan, S. (2009). Smoking in pregnancy and lactation: a review of risks and cessation strategies. *European journal of clinical pharmacology*, 65(4), 325–330. <https://doi.org/10.1007/s00228-008-0609-0>
105. Office of the Surgeon General (US), & Office on Smoking and Health (US). (2004). *The Health Consequences of Smoking: A Report of the Surgeon General*. Centers for Disease Control and Prevention (US).
106. Napierala, M., Mazela, J., Merritt, T. A., & Florek, E. (2016). Tobacco smoking and breastfeeding: Effect on the lactation process, breast milk composition and infant development. A critical review. *Environmental research*, 151, 321–338. <https://doi.org/10.1016/j.envres.2016.08.002>
107. Dorea J. G. (2007). Maternal smoking and infant feeding: breastfeeding is better and safer. *Maternal and child health journal*, 11(3), 287–291. <https://doi.org/10.1007/s10995-006-0172-1>
108. Grana, R., Benowitz, N., & Glantz, S. A. (2014). E-cigarettes: a scientific review. *Circulation*, 129(19), 1972–1986. <https://doi.org/10.1161/CIRCULATIONAHA.114.007667>
109. Centers for Disease Control and Prevention. E-cigarettes and pregnancy. Atlanta, GA: CDC; 2019. Available at: <https://www.cdc.gov/reproductivehealth/maternalinfanthealth/substance-abuse/e-cigarettes-pregnancy.htm> Retrieved August 22, 2022
110. Spindel, E. R., & McEvoy, C. T. (2016). The Role of Nicotine in the Effects of Maternal Smoking during Pregnancy on Lung Development and Childhood Respiratory Disease. Implications for Dangers of E-Cigarettes. *American journal of respiratory and critical care medicine*, 193(5), 486–494. <https://doi.org/10.1164/rccm.201510-2013PP>

## SECTION 2: HARM REDUCTION

111. Whittington, J. R., Simmons, P. M., Phillips, A. M., Gammill, S. K., Cen, R., Magann, E. F., & Cardenas, V. M. (2018). The Use of Electronic Cigarettes in Pregnancy: A Review of the Literature. *Obstetrical & gynecological survey*, 73(9), 544–549. <https://doi.org/10.1097/OGX.0000000000000595>

112. McDonnell, B. P., Dicker, P., & Regan, C. L. (2020). Electronic cigarettes and obstetric outcomes: a prospective observational study. *BJOG : an international journal of obstetrics and gynaecology*, 127(6), 750–756. <https://doi.org/10.1111/1471-0528.16110>

113. Wang, X., Lee, N. L., & Burstyn, I. (2020). Smoking and use of electronic cigarettes (vaping) in relation to preterm birth and small-for-gestational-age in a 2016 U.S. national sample. *Preventive medicine*, 134, 106041. <https://doi.org/10.1016/j.ypmed.2020.106041>

114. Shittu, A., Kumar, B. P., Okafor, U., Berkelhamer, S., Goniewicz, M. L., & Wen, X. (2021). Changes in e-cigarette and cigarette use during pregnancy and their association with small-for-gestational-age birth. *American journal of obstetrics and gynecology*, S0002-9378(21)02583-7. Advance online publication. <https://doi.org/10.1016/j.ajog.2021.11.1354>

115. Bowker, K., Ussher, M., Cooper, S., Orton, S., Coleman, T., & Campbell, K. A. (2020). Addressing and Overcoming Barriers to E-Cigarette Use for Smoking Cessation in Pregnancy: A Qualitative Study. *International journal of environmental research and public health*, 17(13), 4823. <https://doi.org/10.3390/ijerph17134823>

116. DeVito, E. E., Fagle, T., Allen, A. M., Pang, R. D., Petersen, N., Smith, P. H., & Weinberger, A. H. (2021). Electronic Nicotine Delivery Systems (ENDS) Use and Pregnancy I: ENDS Use Behavior During Pregnancy. *Current addiction reports*, 8(3), 347–365. <https://doi.org/10.1007/s40429-021-00380-w>

## SECTION 3: NAVIGATING THE HEALTHCARE + LEGAL SYSTEMS

1. Vincent, E. C., Zebelman, A., Goodwin, C., & Stephens, M. M. (2006). Clinical inquiries. What common substances can cause false positives on urine screens for drugs of abuse?. *The Journal of family practice*, 55(10), 893–897.
2. Lester, B. M., Andreozzi, L., & Appiah, L. (2004). Substance use during pregnancy: time for policy to catch up with research. *Harm reduction journal*, 1(1), 5. <https://doi.org/10.1186/1477-7517-1-5>
3. McMillin, G. A., Slawson, M. H., Marin, S. J., & Johnson-Davis, K. L. (2013). Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management. *Journal of pain & palliative care pharmacotherapy*, 27(4), 322–339. <https://doi.org/10.3109/15360288.2013.847889>
4. National Advocates for Pregnant Women. (2019, March). Clinical drug testing of pregnant women and newborns - New York. National Advocates for Pregnant Women. Retrieved October 2, 2022, from [https://www.nationaladvocatesforpregnantwomen.org/clinical\\_drug\\_testing\\_of\\_pregnant\\_women\\_and\\_newborns/](https://www.nationaladvocatesforpregnantwomen.org/clinical_drug_testing_of_pregnant_women_and_newborns/)
5. Committee opinion no. 633: Alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. (2015). *Obstetrics and gynecology*, 125(6), 1529–1537. <https://doi.org/10.1097/01.AOG.0000466371.86393.9b>
6. Bell S. G. (2016). Drug Screening in Neonates. *Neonatal network : NN*, 35(5), 321–326. <https://doi.org/10.1891/0730-0832.35.5.321>
7. Kohsman M. G. (2016). Ethical Considerations for Perinatal Toxicology Screening. *Neonatal network : NN*, 35(5), 268–276. <https://doi.org/10.1891/0730-0832.35.5.268>
8. Substance Abuse and Mental Health Services Administration. (2017, January 23). The Federal Register. *Federal Register :: Request Access*. Retrieved October 2, 2022, from <https://www.federalregister.gov/documents/2017/01/23/2017-00979/mandatory-guidelines-for-federal-workplace-drug-testing-programs>
9. Terplan, M., & Minkoff, H. (2017). Neonatal Abstinence Syndrome and Ethical Approaches to the Identification of Pregnant Women Who Use Drugs. *Obstetrics and gynecology*, 129(1), 164–167. <https://doi.org/10.1097/AOG.0000000000001781>
10. New York Consolidated Laws, Family Court Act. FCT §§ 412(1), 413; N.Y. Family Court Act §1012(f) (i)(B).

## SECTION 4: PRENATAL CARE

1. Hayes, J. S., Dreher, M. C., & Nugent, J. K. (1988). Newborn outcomes with maternal marijuana use in Jamaican women. *Pediatric nursing*, 14(2), 107–110.
2. Westfall, R. E., Janssen, P. A., Lucas, P., & Capler, R. (2006). Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against 'morning sickness'. *Complementary therapies in clinical practice*, 12(1), 27–33. <https://doi.org/10.1016/j.ctcp.2005.09.006>
3. Alaniz, V. I., Liss, J., Metz, T. D., & Stickrath, E. (2015). Cannabinoid hyperemesis syndrome: a cause of refractory nausea and vomiting in pregnancy. *Obstetrics and gynecology*, 125(6), 1484–1486. <https://doi.org/10.1097/AOG.0000000000000595>
4. Roberson, E. K., Patrick, W. K., & Hurwitz, E. L. (2014). Marijuana use and maternal experiences of severe nausea during pregnancy in Hawai'i. *Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health*, 73(9), 283–287.
5. El-Mohandes, A., Herman, A. A., Nabil El-Khorazaty, M., Katta, P. S., White, D., & Grylack, L. (2003). Prenatal care reduces the impact of illicit drug use on perinatal outcomes. *Journal of perinatology : official journal of the California Perinatal Association*, 23(5), 354–360. <https://doi.org/10.1038/sj.jp.7210933>

## SECTION 5: LABOR + CHILDBIRTH

None

## SECTION 6: POSTPARTUM CARE

1. Schiff, D. M., Nielsen, T., Terplan, M., Hood, M., Bernson, D., Diop, H., Bharel, M., Wilens, T. E., LaRochelle, M., Walley, A. Y., & Land, T. (2018). Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. *Obstetrics and gynecology*, 132(2), 466–474. <https://doi.org/10.1097/AOG.0000000000002734>
2. Committee opinion no. 496: At-risk drinking and alcohol dependence: obstetric and gynecologic implications. (2011). *Obstetrics and gynecology*, 118(2 Pt 1), 383–388. <https://doi.org/10.1097/AOG.0b013e31822c9906>
3. Liston J. (1998). Breastfeeding and the use of recreational drugs--alcohol, caffeine, nicotine and marijuana. *Breastfeeding review : professional publication of the Nursing Mothers' Association of Australia*, 6(2), 27–30.
4. Sachs, H. C., & Committee On Drugs (2013). The transfer of drugs and therapeutics into human breast milk: an update on selected topics. *Pediatrics*, 132(3), e796–e809. <https://doi.org/10.1542/peds.2013-1985>
5. Iqbal, M. M., Sobhan, T., & Ryals, T. (2002). Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. *Psychiatric services (Washington, D.C.)*, 53(1), 39–49. <https://doi.org/10.1176/appi.ps.53.1.39>
6. Bertrand, K. A., Hanan, N. J., Honerkamp-Smith, G., Best, B. M., & Chambers, C. D. (2018). Marijuana Use by Breastfeeding Mothers and Cannabinoid Concentrations in Breast Milk. *Pediatrics*, 142(3), e20181076. <https://doi.org/10.1542/peds.2018-1076>

## SECTION 6: POSTPARTUM CARE

7. Perez-Reyes, M., & Wall, M. E. (1982). Presence of delta9-tetrahydrocannabinol in human milk. *The New England journal of medicine*, 307(13), 819–820.  
<https://doi.org/10.1056/NEJM198209233071311>
8. Hill, M., & Reed, K. (2013). Pregnancy, breast-feeding, and marijuana: a review article. *Obstetrical & gynecological survey*, 68(10), 710–718.  
<https://doi.org/10.1097/01.ogx.0000435371.51584.d1>
9. Braillon, A., & Bewley, S. (2018). Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation. *Obstetrics and gynecology*, 131(1), 164.  
<https://doi.org/10.1097/AOG.0000000000002429>
10. Section on Breastfeeding (2012). Breastfeeding and the use of human milk. *Pediatrics*, 129(3), e827–e841. <https://doi.org/10.1542/peds.2011-3552>
11. Reece-Stremtan, S., & Marinelli, K. A. (2015). ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. *Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine*, 10(3), 135–141.  
<https://doi.org/10.1089/bfm.2015.9992>
12. Metz, T. D., & Stickrath, E. H. (2015). Marijuana use in pregnancy and lactation: a review of the evidence. *American journal of obstetrics and gynecology*, 213(6), 761–778.  
<https://doi.org/10.1016/j.ajog.2015.05.025>
13. National Library of Medicine. (n.d.). Drugs and lactation database (lactmed) - NCBI bookshelf. LactMed. Retrieved October 2, 2022, from <https://www.ncbi.nlm.nih.gov/books/NBK501922/>
14. Dashe, J. S., Jackson, G. L., Olscher, D. A., Zane, E. H., & Wendel, G. D., Jr (1998). Opioid detoxification in pregnancy. *Obstetrics and gynecology*, 92(5), 854–858.  
[https://doi.org/10.1016/s0029-7844\(98\)00312-3](https://doi.org/10.1016/s0029-7844(98)00312-3)
15. Bartu, A., Dusci, L. J., & Ilett, K. F. (2009). Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. *British journal of clinical pharmacology*, 67(4), 455–459. <https://doi.org/10.1111/j.1365-2125.2009.03366.x>
16. Cressman, A. M., Koren, G., Pupco, A., Kim, E., Ito, S., & Bozzo, P. (2012). Maternal cocaine use during breastfeeding. *Canadian family physician Medecin de famille canadien*, 58(11), 1218–1219.
17. Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017). The Safety of Ingested Caffeine: A Comprehensive Review. *Frontiers in psychiatry*, 8, 80. <https://doi.org/10.3389/fpsy.2017.00080>
18. La Leche League International. (2021, June 1). Breastfeeding and caffeine. La Leche League International. Retrieved October 2, 2022, from <https://www.llli.org/breastfeeding-info/caffeine/>
19. Napierala, M., Mazela, J., Merritt, T. A., & Florek, E. (2016). Tobacco smoking and breastfeeding: Effect on the lactation process, breast milk composition and infant development. A critical review. *Environmental research*, 151, 321–338.  
<https://doi.org/10.1016/j.envres.2016.08.002>
20. Dorea J. G. (2007). Maternal smoking and infant feeding: breastfeeding is better and safer. *Maternal and child health journal*, 11(3), 287–291. <https://doi.org/10.1007/s10995-006-0172-1>
21. Vennemann, M. M., Bajanowski, T., Brinkmann, B., Jorch, G., Yücesan, K., Sauerland, C., Mitchell, E. A., & GeSID Study Group (2009). Does breastfeeding reduce the risk of sudden infant death syndrome?. *Pediatrics*, 123(3), e406–e410.  
<https://doi.org/10.1542/peds.2008-2145>